Cancer Screening Patterns Among Current, Former, and Never Smokers in the United States, 2010-2015

Nina N. Sanford, MD; David J. Sher, MD, MPH; Santino Butler, MA; Xiaohan Xu, MS; Chul Ahn, PhD; Anthony V. D'Amico, MD, PhD; Timothy Rebbeck, PhD; Ayal A. Aizer, MD, MHS; Brandon A. Mahal, MD

Abstract

**IMPORTANCE** National guidelines recommend screening for several cancer types, yet screening rates remain below target. To date, cancer screening patterns by smoking status, a major cancer risk factor, are unknown.

**OBJECTIVE** To assess cancer screening patterns among individuals who never smoked (never smokers), formerly smoked (former smokers), and currently smoke (current smokers) in the United States.

**DESIGN, SETTING, AND PARTICIPANTS** This cross-sectional study assessed data from the National Health Interview Survey years 2010, 2013, and 2015. Adult participants (aged ≥18 years) who had never reported a cancer diagnosis were included in the analysis. Data were analyzed from August 1, 2018, through February 1, 2019.

**EXPOSURES** Receipt of cancer screening, including colonoscopy, mammography, prostate-specific antigen testing, and Papanicolaou test per the US Preventive Services Task Force guidelines.

**MAIN OUTCOMES AND MEASURES** Multivariable logistic regression defined adjusted odds ratios (AORs) and 95% CIs for undergoing cancer screening by smoking status. Among participants who received a specific screening test, AORs and 95% CIs of receiving the test within guideline-recommended intervals were also assessed.

**RESULTS** Among 83,176 participants (45,851 [55.1%] women; mean [SD] age, 47 [18] years), 51,014 (61.3%) were never smokers; 17,235 (20.7%), former smokers; and 14,927 (17.9%), current smokers. Compared with never smokers, current smokers were less likely to ever have received a colonoscopy (43.8% vs 57.7%; AOR, 0.74; 95% CI, 0.68-0.82; P < .001), mammogram (88.8% vs 93.3%; AOR, 0.70; 95% CI, 0.57-0.87; P = .001), or prostate-specific antigen test (46.1% vs 60.8%; AOR, 0.76; 95% CI, 0.64-0.90; P = .001). Among those who had ever received a specific screening test, current smokers were less likely to have undergone colonoscopy (92.1% vs 95.1%; AOR, 0.75; 95% CI, 0.59-0.96; P = .02), mammography (62.4% vs 79.4%; AOR, 0.52; 95% CI, 0.45-0.60; P < .001), or Papanicolaou test (80.9% vs 90.8%; AOR, 0.61; 95% CI, 0.56-0.67; P < .001) within the recommended time frame compared with never smokers. Former smokers were more likely than never smokers to undergo any of the screening studies evaluated, with the exception of prostate-specific antigen screening (colonoscopy, 65.2% vs 57.7%; AOR, 1.20; 95% CI, 1.12-1.30; P < .001; mammography, 95.7% vs 93.3%; AOR, 1.35; 95% CI, 1.07-1.70; P = .01; Papanicolaou test, 97.6% vs 91.4%; AOR, 2.51; 95% CI, 1.93-3.26; P < .001).

(continued)
CONCLUSIONS AND RELEVANCE  This study found that current smokers appeared to be less likely to receive guideline-concordant screening studies for breast, prostate, and colorectal cancer compared with never smokers. Further research is needed to identify barriers to screening among current smokers with the goal of increasing acceptance and uptake of cancer screening among this population at high risk of cancer.

JAMA Network Open. 2019;2(5):e193759. doi:10.1001/jamanetworkopen.2019.3759

Introduction

The widespread use of cancer screening has reduced mortality due to several cancer types, including cervical and colorectal, during the past several decades.1-3 Healthy People 2020 was launched in 2010 with objectives to promote evidence-based cancer screening per US Preventive Services Task Force (USPSTF) recommendations during the upcoming decade.4 A 2015 publication showed that most US populations did not meet Healthy People 2020 targets for cancer screening and that significant disparities in screening uptake existed based on race/ethnicity, income, and educational attainment.5

Recent reports, however, have not assessed the association between smoking status and adherence to USPSTF cancer screening guidelines. Since the USPSTF gave lung cancer screening a grade B recommendation in 2013, rates of low-dose computed tomography of the chest have increased, albeit not without concerns regarding slow uptake in eligible individuals and overuse in others.6 In addition to lung cancer, smoking has been linked to cancer risk at additional sites, including the colorectal tract and cervix, with emerging evidence on other cancer types.7,8 Thus, although smoking cessation remains the most critical cancer prevention behavior, individuals who smoke may potentially derive the greatest benefit from improved cancer screening to detect occult disease at an earlier stage. As such, an assessment of cancer screening patterns among smokers is needed. We used a comprehensive nationwide database to examine cancer screening behaviors by smoking status.

Methods

Data Source

The National Health Interview Survey (NHIS) is a cross-sectional household survey of noninstitutionalized civilian adults living in the United States that assesses a wide range of health status and utilization measures.9 The NHIS was first administered in 1957 and uses a multistage probability design to ensure broad geographic representation. Sample weights are provided for each individual, permitting inference on national prevalence. Beginning in 1987, the NHIS has periodically administered a cancer control supplement focusing on issues pertaining to knowledge, attitudes, and practices of cancer-related health behaviors, screening, and risk assessment. Harmonized data were obtained through the Integrated Health Interview Series.10 Data for each study were collected in 2010, 2013, and 2015. The NHIS is overseen by the National Center for Health Statistics research ethics review board. Survey participants provided verbal informed consent. The institutional review board of University of Texas Southwestern Medical Center, Dallas, deemed this study to be exempt from ethics review given the use of public deidentified data. Data and analyses are presented in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cross-sectional studies.11

Population

Our study population included adults (aged ≥18 years) surveyed in 2010, 2013, and 2015, the only years since 2010 for which cancer screening data were available. Participants who reported ever
having a diagnosis of cancer were excluded (7738 out of 90,914 total population). Additional demographic variables, including smoking status, age, sex, race, ethnicity, income, insurance status, and educational attainment, were queried. For smoking status, participants were asked "Have you smoked at least 100 cigarettes during your entire life?" Those who responded no were categorized as individuals who never smoked (never smokers). Those who responded yes were further asked "Do you NOW smoke cigarettes every day, some days, or not at all?" and categorized as individuals who currently smoke every day, who currently smoke some days, or who formerly smoked (former smokers), respectively. For the purpose of our analysis, individuals who reported currently smoking every day and some days were combined into the classification current smokers. Participants who were current smokers were also asked whether they had attempted quitting for more than 1 day during the past year. In addition, a 9-item comorbidity index was created based on self-reported chronic conditions, including hypertension, coronary heart disease, stroke, chronic obstructive pulmonary disease, asthma, diabetes, arthritis, hepatitis, and weak or failing kidneys. Participants were categorized as having 0, 1, or 2 or more chronic conditions.

Cancer Screening Measures
We examined the following 4 cancer screening measures: colonoscopy, testing for prostate-specific antigen (PSA) level, mammography, and Papanicolaou test. We did not evaluate use of screening computed tomography of the chest for smokers because an analysis would have been confounded by indication. Participants were first asked whether they had ever undergone the specific screening measure. Those who answered yes were then asked when their most recent screening test occurred.

The most recent USPSTF guidelines were used for age and frequency of colonoscopy, Papanicolaou test, PSA testing, and mammography. The USPSTF grades include A and B for recommends this service, C for recommends selectively offering or providing this service to individual patients based on professional judgment and patient preferences, and D for recommends against this service. The guidelines included colonoscopy within 10 years for adults aged 50 to 75 years (grade A), Papanicolaou test within 3 years for women aged 21 to 65 years without prior hysterectomy (grade A), PSA testing for men aged 55 to 69 years (grade D, upgraded to C in 2017), and biennial mammography for women aged 50 to 74 years (grade B). Notably, prostate cancer screening guidelines per USPSTF have changed significantly during the last decade. In 2008, screening was given a grade I recommendation (insufficient evidence to assess benefits of balance and harms) for men younger than 75 years and grade D for men 75 years and older. In 2012, the recommendation was changed to grade D for all men, and more recently in 2017, men aged 55 to 69 years were given a grade C recommendation, whereas the recommendation for those 70 years and older remained grade D.

Statistical Analysis
Baseline Characteristics
Baseline characteristics of the cohort stratified by smoking status were reported. The Kruskal-Wallis and χ² tests compared distributions of continuous and categorical covariates, respectively.

Cancer Screening by Smoking Status
The primary independent variable of interest was smoking status, and the primary end point of interest was receipt of cancer screening. For each of the screening tests (colonoscopy, PSA test, mammography, and Papanicolaou test), multivariable logistic regression defined adjusted odds ratio (AOR) and associated 95% CIs of cancer screening by smoking status. Additional variables adjusted for and included in the models were age, sex, race, ethnicity, annual family income, insurance status, highest educational level attained, and comorbidity score. Weighted prevalence of cancer screening by smoking status was also estimated.

For participants who reported ever undergoing a specific cancer screening test, multivariable logistic regression defined the AOR and 95% CI of receiving screening within the recommended time
frame (adjusted for the variables listed above) as defined by the USPSTF guidelines above; weighted prevalence of this end point was also assessed. As a secondary end point, the aforementioned analyses were repeated among current smokers who attempted to quit smoking during the past 12 months vs not as the independent variable of interest. Outcomes were measured at the time of survey in this cross-sectional study with no follow-up time. All analyses were restricted to the specific populations for whom testing was recommended per USPSTF guidelines (eg, analyses for mammography included only women aged 50-74 years).

**Prostate Cancer Screening by Smoking Status Stratified by Year**

Given changing prostate cancer screening recommendations, multivariable logistic regression defined the AOR and 95% CI of ever receiving PSA testing for men aged 50 to 70 years in 2010, 2013, and 2015. Models were adjusted for demographic and socioeconomic status variables described above. This age range was chosen because it comprehensively includes age cutoffs in previous USPSTF guidelines along with those issued by other medical societies. These organizations include the American Cancer Society, which recommends discussion of PSA testing starting at age 50 years for men at average risk; the American Urological Society, which encourages men aged 55 to 69 years to undergo shared decision making regarding PSA testing; and the Mayo Clinic, which recommends screening for men aged 50 to 70 years.

Sample weighting stratified by year was used for all analyses to produce nationally representative estimates. Statistical testing was 2-sided, with \( \alpha = .05 \). All AORs and accompanying 95% CIs were generated using multivariable logistic regressions. Analyses were performed with Stata/SE, version 15.1 (StataCorp), or R, version 3.0.2 (R Project for Statistical Computing).

**Results**

**Baseline Characteristics**

Among 83,176 participants (45,851 [55.1%] women; mean [SD] age, 47 [18] years), 51,014 (61.3%) were never smokers; 17,235 (20.7%), former smokers; and 14,927 (17.9%), current smokers (Table 1). Former smokers were older (mean [SD] age, 55 [17] years; \( P < .001 \)) than never smokers (mean [SD] age, 45 [18] years) or current smokers (mean [SD] age, 44 [15] years). Compared with former and never smokers, current smokers tended to have lower annual family income (<$35,000/y, 34.9% and 36.8%, respectively, vs 53.1%), were more likely to be uninsured (uninsured, 10.9% and 15.5%, respectively, vs 26.0%), and achieved lower educational levels (≤5 years of college, 9.4% and 12.4%, respectively, vs 3.4%). (Table 1).

**Cancer Screening by Smoking Status**

Compared with never smokers, current smokers meeting USPSTF criteria for screening were less likely to ever have received a colonoscopy (43.8% vs 57.7%; AOR, 0.74; 95% CI, 0.68-0.82; \( P < .001 \)), mammogram (88.8% vs 93.3%; AOR, 0.70; 95% CI, 0.57-0.87; \( P = .001 \)), or PSA test (46.1% vs 60.8%; AOR, 0.76; 95% CI, 0.64-0.90; \( P = .001 \)) (Figure 1A and Figure 2A). In contrast, current smokers were more likely to have ever undergone a Papanicolaou test (95.9% vs 91.4%; AOR, 2.25; 95% CI, 1.82-2.77; \( P < .001 \)) compared with never smokers. Former smokers were more likely than never smokers to undergo any of the screening studies evaluated, with the exception of a PSA test (colonoscopy, 65.2% vs 57.7% [AOR, 1.20; 95% CI, 1.12-1.30; \( P < .001 \)]; mammography, 95.7% vs 93.3% [AOR, 1.35; 95% CI, 1.07-1.70; \( P = .01 \)]; Papanicolaou test, 97.6% vs 91.4% [AOR, 2.51; 95% CI, 1.93-3.26; \( P < .001 \)] (Figure 1A and Figure 2A).

Among those who had ever received a specific screening test, current smokers were less likely to have undergone colonoscopy (92.1% vs 95.1%; AOR, 0.75; 95% CI, 0.59-0.96; \( P = .02 \)), mammography (62.4% vs 79.4%; AOR, 0.52; 95% CI, 0.45-0.60; \( P < .001 \)), or Papanicolaou test (80.9% vs 90.8%; AOR, 0.61; 95% CI, 0.56-0.67; \( P < .001 \)) within the recommended time frame compared with never smokers (Figure 1B). For example, 62.4% of current female smokers aged 50...
to 74 years had undergone mammography in the previous 2 years, compared with 79.5% of never smokers and 77.8% of former smokers. The proportions of participants who had ever undergone a screening study and who had received the screening study within the recommended interval are shown in Figure 2. Notably, the absolute differences in screening rates between never and current smokers for PSA screening and colonoscopy approached 15%, whereas that for mammography was more modest at 4.5%.

Among 14,927 current smokers, 7,161 (48.0%) reported attempting to quit smoking for at least 1 day during the past 12 months. Those who had attempted smoking cessation were more likely to have ever undergone colonoscopy (47.6% vs 41%; AOR, 1.25; 95% CI, 1.07-1.46; \( P = .005 \)) and mammography (92.6% vs 86.0%; AOR, 2.02; 95% CI, 1.38-2.94; \( P < .001 \)) compared with those who had not and also more likely to undergo mammography (66.3% vs 59.1%; AOR, 1.30; 95% CI, 1.02-1.66; \( P = .03 \)) and Papanicolaou test (83.9% vs 77.4%; AOR, 1.30; 95% CI, 1.06-1.58; \( P = .01 \)) within the recommended time frame (Table 2).

### Table 1. Distribution of Baseline Patient Characteristics by Smoking Status Among US Participants Aged 18 and Older Not Reporting a History of Cancer Surveyed in 2010, 2013, and 2015a

| Smoking Status | Total (N = 83,176) | Never (n = 51,014) | Former (n = 17,235) | Current (n = 14,927) |
|---------------|-------------------|-------------------|--------------------|---------------------|
| Sex           |                   |                   |                    |                     |
| Male          | 37,325 (44.9)     | 20,465 (40.1)     | 9,087 (52.7)       | 7,773 (52.1)        |
| Female        | 45,851 (55.1)     | 30,549 (59.9)     | 8,148 (47.3)       | 7,154 (47.9)        |
| Raceb         |                   |                   |                    |                     |
| White         | 62,620 (75.3)     | 37,015 (72.6)     | 14,244 (82.6)      | 11,361 (76.1)       |
| Black         | 13,456 (16.2)     | 8,827 (17.3)      | 1,975 (11.5)       | 2,654 (17.8)        |
| Native Alaskan or American | 1,032 (1.2) | 562 (1.1) | 212 (1.2) | 258 (1.7) |
| Chinese       | 5,532 (6.7)       | 4,266 (8.4)       | 709 (4.1)          | 557 (3.7)           |
| Unknown/multiple | 536 (0.6)  | 344 (0.7) | 95 (0.6) | 97 (0.6) |
| Ethnicityb    |                   |                   |                    |                     |
| Non-Spanish/non-Hispanic/non-Latino | 67,722 (81.4) | 39,678 (77.8) | 15,044 (87.3) | 13,000 (87.1) |
| Spanish, Hispanic, or Latino | 15,454 (18.6) | 11,336 (22.2) | 2,191 (12.7) | 1,927 (12.9) |
| Age, mean (SD), y | 47 (18)   | 45 (18) | 55 (17) | 44 (15) |
| Annual income, US$ |             |                   |                    |                     |
| 0-34,999      | 32,697 (39.3)     | 18,757 (36.8)     | 6,020 (34.9)       | 7,792 (53.1)        |
| 35,000-74,999 | 23,842 (28.7)     | 14,474 (28.4)     | 5,247 (30.4)       | 4,121 (27.6)        |
| 75,000-99,999 | 7,963 (9.6)       | 5,081 (10.0)      | 1,819 (10.6)       | 1,063 (7.1)         |
| ≥100,000      | 13,420 (16.1)     | 9,298 (18.2)      | 2,976 (17.3)       | 1,146 (7.7)         |
| Not ascertained/unknown | 5,254 (6.3)  | 3,404 (6.7)      | 1,173 (6.8) | 677 (4.5) |
| Insurance     |                   |                   |                    |                     |
| Insured       | 69,189 (83.2)     | 42,884 (84.1)     | 15,310 (88.8)      | 10,995 (73.7)       |
| Not insured   | 13,677 (16.4)     | 7,907 (15.5)      | 1,883 (10.9)       | 3,887 (26.0)        |
| Unknown       | 310 (0.4)         | 223 (0.4)         | 42 (0.2)           | 45 (0.3)            |
| Highest educational level attained |             |                   |                    |                     |
| None or grades K-4 | 1,313 (1.6) | 931 (1.8) | 212 (1.2) | 170 (1.1) |
| Grades 5-12   | 32,538 (39.1)     | 17,806 (34.9)     | 6,854 (39.8)       | 7,878 (52.8)        |
| 1-4 y college | 40,023 (48.7)     | 25,717 (50.4)     | 8,489 (49.3)       | 6,317 (42.3)        |
| ≥5 y college  | 8,466 (10.2)      | 6,345 (12.4)      | 1,619 (9.4)        | 502 (3.4)           |
| Unknown       | 336 (0.4)         | 215 (0.4)         | 61 (0.4)           | 60 (0.4)            |
| Comorbidity   |                   |                   |                    |                     |
| 0             | 41,811 (50.3)     | 28,429 (55.7)     | 6,148 (35.7)       | 7,234 (48.5)        |
| 1             | 22,124 (26.6)     | 12,900 (25.3)     | 5,036 (29.2)       | 4,188 (28.1)        |
| ≥2            | 19,241 (23.1)     | 9,685 (19.0)      | 6,051 (35.1)       | 3,505 (23.5)        |

* Data are obtained from the National Health Interview Survey years 2010, 2013, and 2015. Unless otherwise indicated, data are expressed as number (percentage) of participants. Percentages have been rounded and may not total 100. \( P < .001 \) when comparing across smoking status for all baseline characteristics.

b Race and ethnicity were self-reported as captured by the National Health Interview Survey. Participants were asked whether they identified with 1 or more of the following racial groups: white, black/African American, Native Alaskan or American, Chinese, Filipino, Asian Indian, or other Asian. Those reporting Chinese, Filipino, Asian Indian, or other Asian race were grouped as Asian. Participants with multiple races or primary race not releasable were grouped as unknown/multiple. Participants were also asked whether they identified with 1 or more of the following ethnicities: non-Hispanic/non-Spanish origin, Mexican, Mexican American, Puerto Rican, Cuban/Cuban American, Dominican (Dominican Republic), Central or South American, other Latin American (type not specific), other Spanish, or multiple Hispanic. Those reporting any of the ethnicities with the exception of non-Hispanic/non-Spanish origin were categorized as Spanish-Hispanic-Latino.
Prostate Cancer Screening by Smoking Status Stratified by Year

No difference in PSA screening between current and never smokers occurred in 2010 (42.6% vs 50.7%; AOR, 0.85; 95% CI, 0.67-1.10; P = .21) (Table 3). In contrast, the odds of ever undergoing PSA testing were significantly lower in current smokers than never smokers in 2013 (38.3% vs 51.7%; AOR, 0.77; 95% CI, 0.61-0.98; P = .03) and 2015 (39.9% vs 55.1%; AOR, 0.72; 95% CI, 0.56-0.93; P = .01) (with grade D USPSTF recommendations against PSA testing) (Table 3).

Discussion

In this large, contemporary, national survey, current smokers were less likely to receive guideline-concordant screening for breast, prostate, and colorectal cancer than were never smokers after correcting for relevant demographic and socioeconomic factors. In contrast, former smokers were more likely than never smokers to receive breast, prostate, and colorectal cancer screening at...
age-appropriate intervals. Furthermore, among current smokers, those who attempted to quit were more likely to have been screened for breast and colorectal cancer than were smokers who did not attempt to quit.

The lower rate of cancer screening in current smokers despite their increased cancer risk is a concerning paradox. As such, our study has several major public health implications. First, by foregoing age-appropriate cancer screening, smokers are at risk for presenting with later-stage cancers. Smoking is associated with a wide range of adverse outcomes after a cancer diagnosis, and a later stage of diagnosis could therefore further exacerbate cancer outcomes among this population. A previously published report including 954,029 individuals found that current smokers had 17% excess mortality compared with those who never smoked. In that study, current smoking was associated with increased risk of death due to cancers of the prostate and breast, disease sites where a causal link between smoking and cancer development has not yet been firmly established. Our study raises the hypothesis that lower rates of screening among current smokers could lead to more advanced presentation and contribute to their worse outcomes. Second, our study identifies a high-risk population that appears to be receiving suboptimal cancer screening that would benefit from measures to promote screening and to meet Healthy People 2020 targets. Although further research is needed to elucidate specific barriers to screening for individuals who smoke, policy and interventions may be warranted to support appropriate cancer screening among this population. Importantly, increased efforts directed toward cancer screening in individuals who smoke may also provide an impetus and greater support for cessation of tobacco use.

The reasons for lower cancer screening rates among smokers are likely multifactorial. Prior studies examining beliefs about cancer and health-seeking behaviors found that current smokers were more likely to hold pessimistic and avoidant beliefs about cancer. In particular, current smokers were more likely to view cancer as a death sentence and to believe that a diagnosis of cancer would preclude continuation of normal activities. These observations suggest that smokers’ awareness regarding the negative effects of tobacco use may actually discourage them from undergoing cancer screening. Prior research has also shown an association between heavy smoking and other adverse health choices, such as consuming junk food, decreased exercise, and greater alcohol use.

![Figure 2. Weighted Prevalence of Receiving Cancer Screening](https://jamanetwork.com/)

| Screening Study | Population Receiving Screening, % |
|-----------------|-----------------------------------|
| Colonoscopy     | 100                               |
| Mammography     | 100                               |
| PSA Test        | 100                               |
| Papanicolaou test | 100                             |

Error bars indicate 95% CIs; PSA, prostate-specific antigen.

- Includes adults aged 50 to 75 years.
- Includes women aged 50 to 74 years.
- Indicates within 10 years.
- Indicates within 2 years.
- Indicates within 1 year.
- Indicates within 3 years.
clustering of unhealthy practices raises the hypothesis that health behavior choices, including the
decision to undergo cancer screening, may be a reflection of personal biases regarding health status.
Former smokers and the subset of current smokers who have recently attempted to quit may feel
especially motivated to take initiatives to optimize their long-term health. Ultimately, further
research is needed to better understand the multifactorial causes of the observed cancer screening
disparities among smokers.

Our finding that current and former smokers were more likely to undergo Papanicolaou tests
was not surprising, given the multiple indications for Papanicolaou tests outside of cancer screening.
We hypothesize 3 potential explanations for this association. First, Papanicolaou tests can be
performed efficiently in office by a primary care physician or a gynecologist. In contrast,
colonoscopies or mammograms require an additional visit, preprocedural preparation, and/or an
appointment with a specialist. Notably however, PSA screening can also be easily performed in office;
thus, this rationale would not explain the increased uptake of Papanicolaou tests compared with PSA
testing among smokers. Second, prior research has shown an association between smoking and
sexually transmitted infections. Seeking care for sexually transmitted infections may present
smokers an opportunity to undergo Papanicolaou tests. Third, studies have suggested an association
between smoking and sexual activity. Young women who are interested in becoming sexually
active may approach their physicians regarding contraception, which historically has been
accompanied by a pelvic examination, including a Papanicolaou test. Accordingly, the rate of ever
having a Papanicolaou test would be higher within this group, but the rate of undergoing

| Table 2. Odds of Ever Undergoing Cancer Screening and Undergoing
| Screening Within the Recommended Time Interval Among Current
| Smokers Who Attempted to Quit in the Past Year vs Those Who Did Not* |
|-----------------|-----------------|-----------------|
| Recommended Screen | Attempted to Quit in Past Year (n = 14,927) | AOR (95% CI)** | P Value |
| Colonoscopy in adults aged 50-75 y (n = 5,246) | | |
| Ever | 1.25 (1.07-1.46) | .005 |
| Within 10 y | 1.22 (0.82-1.84) | .33 |
| Mammography in women aged 50-74 y (n = 2,483) | | |
| Ever | 2.02 (1.38-2.94) | <.001 |
| Within 2 y | 1.30 (1.02-1.66) | .03 |
| PSA test in men aged 55-69 y (n = 1,609) | | |
| Ever | 1.16 (0.87-1.54) | .32 |
| Within 1 y | 1.09 (0.72-1.65) | .68 |
| Papanicolaou test in women aged 21-65 y (n = 5,070) | | |
| Ever | 1.14 (0.79-1.65) | .48 |
| Within 3 y | 1.30 (1.06-1.58) | .01 |

Abbreviations: AOR, adjusted odds ratio; PSA, prostate-specific antigen.

* Includes participants not reporting a cancer diagnosis in the National Health
Interview Survey years 2010, 2013, and 2015. Those not attempting to quit
constituted the reference category for the primary comparison.

** All AORs are adjusted for the following sociodemographic variables: age
(continuous), sex (male [reference] and female), race (white [reference],
black, Alaskan, Asian, and other), ethnicity (non-Hispanic [reference] and
Hispanic), annual family income (0-$34,999 [reference], $35,000-$74,999,
$75,000-$99,999, $100,000, and unknown), insurance status (no coverage
[reference], has coverage, and coverage status unknown), highest educational
level attained (none/kindergarten only [reference], grades 1-8, grades 9-12,
1-4 years of college, 5 years of college, and unknown) and comorbidity score
(0 [reference], 1, and 2).

Excludes women with prior hysterectomy.
Papanicolaou tests within the recommended time frame would be lower, which was observed in our study.

The emerging disparity in PSA testing warrants further discussion. Notably, no difference in odds of undergoing screening was found in 2010, when the USPSTF did not issue guidelines against PSA testing. However, in 2013 and 2015, after PSA testing received a grade D recommendation, current smokers were less likely than never smokers to receive the test. This finding suggests that although guidelines are created to standardize practices, they may allow for existing disparities to become apparent. Since the USPSTF upgraded their recommendations from grade D to C in 2017, current smokers were more likely to receive screening tests in 2013 and 2015 compared to 2010.

### Table 3. Odds of Ever Undergoing PSA Testing Stratified by Year

| Characteristic                | Survey Year      | 2010 (n = 2954) | 2013 (n = 4342) | 2015 (n = 4219) |
|------------------------------|------------------|-----------------|-----------------|-----------------|
|                              |                  | AOR (95% CI)    | P Value         | AOR (95% CI)    | P Value         | AOR (95% CI)    | P Value         |
| Smoking status               |                  |                 |                 |                 |                 |                 |                 |
| Never                        | 1 [Reference]    | 1 [Reference]   | 1 [Reference]   |                 |                 |                 |                 |
| Former                       | 1.26 (1.00-1.57) | .05             | 0.99 (0.81-1.20)| .90             | 1.20 (0.97-1.48)| .10             |                 |                 |
| Current                      | 0.85 (0.67-1.10) | .21             | 0.77 (0.61-0.98)| .03             | 0.72 (0.56-0.93)| .01             |                 |                 |
| Age                          | 1.10 (1.08-1.12) | <.001           | 1.09 (1.07-1.11)| <.001           | 1.07 (1.05-1.09)| <.001           |                 |                 |
| Race                         |                  |                 |                 |                 |                 |                 |                 |
| White                        | 1 [Reference]    | 1 [Reference]   | 1 [Reference]   |                 |                 |                 |                 |
| Black                        | 1.14 (0.88-1.49) | .32             | 1.12 (0.87-1.43)| .37             | 1.10 (0.85-1.44)| .46             |                 |                 |
| Native Alaskan or American   | 0.52 (0.15-1.85) | .31             | 0.86 (0.40-1.85)| .70             | 1.17 (0.55-2.49)| .68             |                 |                 |
| Chinese                      | 0.52 (0.34-0.79) | .002            | 0.49 (0.33-0.72)| <.001           | 0.28 (0.19-0.42)| <.001           |                 |                 |
| Unknown                      | 0.18 (0.02-1.92) | .16             | 0.52 (0.10-2.64)| .43             | 0.99 (0.26-3.82)| .99             |                 |                 |
| Ethnicity                    |                  |                 |                 |                 |                 |                 |                 |
| Non-Spanish/non-Hispanic/non-Latino | 1 [Reference] | 1 [Reference]  | 1 [Reference]   |                 |                 |                 |                 |
| Spanish, Hispanic, or Latino | 0.70 (0.52-0.94) | .02             | 0.79 (0.60-1.04)| .09             | 0.72 (0.55-0.96)| .02             |                 |                 |
| Income, US$                  |                  |                 |                 |                 |                 |                 |                 |
| 0-34 999                     | 1 [Reference]    | 1 [Reference]   | 1 [Reference]   |                 |                 |                 |                 |
| 35 000-74 999                | 1.31 (1.03-1.67) | .03             | 1.58 (1.26-1.99)| <.001           | 1.36 (1.07-1.73)| .01             |                 |                 |
| 75 000-99 999                | 1.49 (1.05-2.11) | .02             | 1.38 (1.00-1.91)| .5              | 1.83 (1.32-2.52)| <.001           |                 |                 |
| ≥100 000                     | 1.81 (1.32-2.47) | <.001           | 2.36 (1.81-3.09)| <.001           | 2.22 (1.68-2.92)| <.001           |                 |                 |
| Unknown                      | 1.92 (1.19-3.09) | .008            | 2.25 (1.56-3.26)| <.001           | 1.56 (1.10-2.21)| .01             |                 |                 |
| Insurance                    |                  |                 |                 |                 |                 |                 |                 |
| Insured                      | 1 [Reference]    | 1 [Reference]   | 1 [Reference]   |                 |                 |                 |                 |
| Not insured                  | 0.54 (0.39-0.74) | <.001           | 0.61 (0.46-0.82)| .001           | 0.58 (0.41-0.82)| .002           |                 |                 |
| Highest educational level attained |                  |                 |                 |                 |                 |                 |                 |
| None or grades K-4           | 1 [Reference]    | 1 [Reference]   | 1 [Reference]   |                 |                 |                 |                 |
| Grades 5-12                  | 1.37 (0.62-3.03) | .44             | 0.60 (0.33-1.11)| .11             | 0.77 (0.36-1.64)| .49             |                 |                 |
| 1-4 y college                | 2.43 (1.09-5.43) | .03             | 0.92 (0.49-1.71)| .78             | 1.24 (0.58-2.67)| .58             |                 |                 |
| ≥5 y college                 | 3.69 (1.57-8.65) | .003            | 1.44 (0.74-2.82)| .29             | 1.96 (0.87-4.40)| .10             |                 |                 |
| Unknown                      | 0.71 (0.16-3.16) | .66             | 0.23 (0.05-1.08)| .06             | 0.36 (0.05-2.52)| .30             |                 |                 |
| Comorbidity, No. (%)         |                  |                 |                 |                 |                 |                 |                 |
| 0                            | 1 [Reference]    | 1 [Reference]   | 1 [Reference]   |                 |                 |                 |                 |
| 1                            | 1.41 (1.12-1.78) | .004            | 2.22 (1.79-2.75)| <.001           | 1.55 (1.23-1.95)| <.001           |                 |                 |
| ≥2                           | 1.74 (1.38-2.20) | <.001           | 2.28 (1.84-2.82)| <.001           | 1.78 (1.41-2.24)| <.001           |                 |                 |

Abbreviations: AOR, adjusted odds ratio; PSA, prostate-specific antigen.

*Includes 11,425 men aged 50 to 70 years in the National Health Interview Survey years 2010, 2013 and 2015.

Race and ethnicity were self-reported as captured by the National Health Interview Survey. Participants were asked whether they identified with 1 or more of the following racial groups: white, black/African American, Native Alaskan or American, Chinese, Filipino, Asian Indian, or other Asian. Those reporting Chinese, Filipino, Asian Indian, or other Asian race were grouped as Asian. Participants with multiple races or primary race not releasable were grouped as unknown/multiple. Participants were also asked whether they identified with 1 or more of the following ethnicities: non-Hispanic/non-Spanish origin, Mexican, Mexican American, Puerto Rican, Cuban/Cuban American, Dominican (republic), Central or South American, other Latin American (type not specific), other Spanish, or multiple Hispanic. Those reporting any of the ethnicities with the exception of non-Hispanic/non-Spanish origin were categorized as Spanish-Hispanic-Latino.
experts foresee an increased uptake in PSA testing overall. We await the next NHIS data release to ascertain how this change may have differentially affected the smoking population.

**Strengths and Limitations**

Most prior research on factors associated with cancer screening have shown a negative association between adherence to screening recommendations and smoking status. However, these studies were conducted before the publication of current screening guidelines, have been limited to women, were based on foreign participants or individuals residing in a specific US state, or only included select cancer types.36-43 These studies are therefore not representative of current nationwide cancer screening trends among the smoking population.

Notwithstanding, our study has notable limitations. First, all data were self-reported, including smoking status and interval since cancer screening. However, research has shown high concordance between patient- and physician-reported smoking behavior.44,45 Published rates on agreement for report of cancer screening appear to vary, with most studies showing higher self-reported rates than what were supported by the medical record.46,47 Second, the survey did not distinguish whether a test was administered for screening or diagnostic purposes. By excluding participants with a cancer diagnosis from our analyses, however, we would expect most tests to have been performed for screening. Third, the timing of follow-up screening can depend on results from the prior examination. Because information was not available regarding results of any prior screening study, we chose the recommended interval for individuals with normal findings, acknowledging that this interval may fall outside the time frame for those with abnormal examination findings. Fourth, our study focused on the primary screening methods for colorectal, prostate, breast, and cervical cancer and did not analyze the association between smoking status and uptake of other test types used less frequently, such as fecal occult blood testing for colorectal cancer. Fifth, given that PSA testing received a grade D recommendation in 2012, the decreased uptake of PSA testing in 2013 and 2015 among smokers does not technically represent lower guideline compliance in this population.

**Conclusions**

Current smokers appear to be less likely to receive cancer screening in accordance with USPSTF guidelines for colorectal, prostate, and breast cancer. Our findings suggest physicians need to be aware of this disparity, which may affect a group of individuals with a baseline higher risk for several cancer types. We recommend a concerted effort from the medical community to identify barriers to screening among smokers to implement strategies to increase acceptance and uptake of cancer screening within this population.
Massachusetts (Mahal).

**Author Contributions:** Dr Sanford and Mahal had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Sanford, Rebbeck, Mahal.

**Acquisition, analysis, or interpretation of data:** Sanford, Sher, Butler, Xu, Ahn, D'Amico, Aizer, Mahal.

**Drafting of the manuscript:** Sanford, Xu, D’Amico, Mahal.

**Critical revision of the manuscript for important intellectual content:** Sanford, Sher, Butler, Ahn, D’Amico, Rebbeck, Aizer, Mahal.

**Statistical analysis:** Sanford, Butler, Xu, Ahn, D’Amico, Aizer, Mahal.

**Administrative, technical, or material support:** Rebbeck.

**Supervision:** Rebbeck.

**Conflict of Interest Disclosures:** Dr Rebbeck reported receiving nonfinancial support from Harvard University, grants from the National Institutes of Health, and nonfinancial support from Dana-Farber Cancer Institute outside the submitted work. Dr Aizer reported receiving grants from Varian Medical Systems outside the submitted work. No other disclosures were reported.

**Funding/Support:** This study was supported by the American Society of Radiation Oncology and the Prostate Cancer Foundation (Dr Mahal).

**Role of the Funder/Sponsor:** The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**REFERENCES**

1. Landy R, Pesola F, Castañón A, Sasieni P. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. *Br J Cancer*. 2016;115(9):1140-1146. doi: 10.1038/bjc.2016.290

2. Levin TR, Corley DA, Jensen CD, et al. Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population. *Gastroenterology*. 2018;155(5):1383-1391.e5. doi:10.1053/j.gastro.2018.07.017

3. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. *N Engl J Med*. 2013;369(12):1095-1105. doi:10.1056/NEJMoa1301969

4. Healthy People 2020. Washington, DC: US Department of Health and Human Services, Office of Disease Prevention and Health Promotion. https://www.healthypeople.gov/2020/topics-objectives/topic/cancer. Updated April 4, 2019. Accessed August 1, 2018.

5. White A, Thompson TD, White MC, et al. Cancer screening test use—United States, 2015. *MMWR Morb Mortal Wkly Rep*. 2017;66(8):201-206. doi:10.15585/mmwr.mm6608a1

6. Huo J, Shen C, Volk RJ, Shih YT. Use of CT and chest radiography for lung cancer screening before and after publication of screening guidelines: intended and unintended uptake. *JAMA Intern Med*. 2017;177(3):439-441. doi:10.1001/jamainternmed.2016.9016

7. Agudo A, Bonet C, Travier N, et al. Impact of cigarette smoking on cancer risk in the European prospective investigation into cancer and nutrition study. *J Clin Oncol*. 2012;30(36):4550-4557. doi:10.1200/JCO.2011.41.0183

8. Botteri E, iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a meta-analysis. *JAMA*. 2008;300(23):2765-2778. doi:10.1001/jama.2008.839

9. Centers for Disease Control and Prevention. National Health Interview Survey: methods. http://www.cdc.gov/nchs/hihs/methods.htm. Updated February 5, 2019. Accessed August 24, 2018.

10. Lynn A, Blewett JA, Rivera D, et al. IPUMS Health Surveys: National Health Interview Survey, Version 6.3 [dataset]. Minneapolis, MN: IPUMS; 2018. doi:10.18128/D070.V6.3.

11. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ*. 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782.AD

12. Gonzales G, Przedworski J, Henning-Smith C. Comparison of health and health risk factors between lesbian, gay, and bisexual adults and heterosexual adults in the united states: results from the National Health Interview Survey. *JAMA Intern Med*. 2016;176(9):1344-1351. doi:10.1001/jamainternmed.2016.3432

13. Ward BW, Joestl SS, Galinsky AM, Dahlhamer JM. Selected diagnosed chronic conditions by sexual orientation: a national study of US adults, 2013. *Prev Chronic Dis*. 2015;12:E192. doi:10.5888/pcd12.150292
14. Royce TJ, Hendrix LH, Stokes WA, Allen IM, Chen RC. Cancer screening rates in individuals with different life expectancies. *JAMA Intern Med*. 2014;174(10):1558-1565. doi:10.1001/jamainternmed.2014.3895

15. Grossman DC, Curry SJ, Owens DK, et al; US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. *JAMA*. 2018;319(18):1901-1913. doi:10.1001/jama.2018.5989

16. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. *JAMA*. 2016;315(23):2564-2575. doi:10.1001/jama.2016.5989

17. Curry SJ, Krist AH, Owens DK, et al; US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. *JAMA*. 2018;320(7):674-686. doi:10.1001/jama.2018.10897

18. US Preventive Services Task Force. Final recommendation statement: breast cancer: screening. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/breast-cancer-screening1. Updated January 2016. Accessed August 1, 2018.

19. Moyer VA; US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2014;160(5):330-338. doi:10.1056/NEJMsa1312535

20. US Preventive Services Task Force. Grade definitions. https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions. Published October 2018. Accessed March 12, 2019.

21. US Preventive Services Task Force. Final update summary: prostate cancer: screening. 2008. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/prostate-cancer-screening2008. Published August 2008. Accessed August 1, 2018.

22. US Preventive Services Task Force. Final update summary: prostate cancer: screening. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/prostate-cancer-screening. Published September 2016. Accessed August 1, 2018.

23. National Cancer Institute. American Cancer Society recommendations for prostate cancer early detection. https://www.cancer.org/cancer/prostate-cancer/early-detection/acs-recommendations.html. Updated April 14, 2016. Accessed August 29, 2018.

24. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. *J Urol*. 2013;190(2):419-426. doi:10.1016/j.juro.2013.04.119

25. Mayo Clinic. Prostate cancer screening: should you get a PSA test? http://www.mayoclinic.org/tests-procedures/psa-test/in-depth/prostate-cancer/art-20048087. Published 2018. Accessed August 1, 2018.

26. U.S. Department of Health and Human Services. *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General*. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.

27. Gajdos C, Hawn MT, Campagna EJ, Henderson WG, Singh JA, Houston T. Adverse effects of smoking on postoperative outcomes in cancer patients. *Ann Surg Oncol*. 2012;19(5):1430-1438. doi:10.1245/s10434-011-2128-y

28. Carter BD, Abnet CC, Feskanich D, et al. Smoking and mortality—beyond established causes. *N Engl J Med*. 2015;372(7):631-640. doi:10.1056/NEJMc1407211

29. Quaife SL, McEwen A, Janes SM, Wardle J. Smoking is associated with pessimistic and avoidant beliefs about cancer: results from the International Cancer Benchmarking Partnership. *Br J Cancer*. 2015;112(11):1799-1804. doi:10.1038/bjc.2015.148

30. Niederdeppe J, Levy AG. Fatalistic beliefs about cancer prevention and three prevention behaviors. Cancer Epidemiol Biomarkers Prev. 2007;16(5):998-1003. doi:10.1158/1055-9965.EPI-06-0608

31. Lohse T, Rohrmann S, Bopp M, Faeh D. Heavy smoking is more strongly associated with general unhealthy lifestyle than obesity and underweight. *PLoS One*. 2016;11(2):e0148563. doi:10.1371/journal.pone.0148563

32. Pronk NP, Anderson LH, Crain AL, et al. Meeting recommendations for multiple healthy lifestyle factors: prevalence, clustering, and predictors among adolescent, adult, and senior health plan members. *Am J Prev Med*. 2004;27(2)(suppl):S25-33. doi:10.1016/j.amepre.2004.04.022

33. Kataja V, Syrjänen S, Ylisirki A, et al. Risk factors associated with cervical human papillomavirus infections: a case-control study. *Am J Epidemiol*. 1993;138(9):735-745. doi:10.1093/oxfordjournals.aje.a116911

34. Diaz P, Ferketich A. Smoking and HIV: confronting the epidemic. *Lancet HIV*. 2018;5(3):e109-e110. doi:10.1016/S2352-3018(18)30001-8
35. Camenga DR, Klein JD, Roy J. The changing risk profile of the American adolescent smoker: implications for prevention programs and tobacco interventions. J Adolesc Health. 2006;39(1):120.e1-120.e10. doi:10.1016/j.jadohealth.2005.10.014

36. Byrne MM, Davila EP, Zhao W, et al. Cancer screening behaviors among smokers and non-smokers. Cancer Epidemiol. 2010;34(5):611-617. doi:10.1016/j.canep.2010.06.017

37. Carlos RC, Fendrick AM, Patterson SK, Bernstein SJ. Associations in breast and colon cancer screening behavior in women. Acad Radiol. 2005;12(4):451-458. doi:10.1016/j.acra.2004.12.024

38. Carlos RC, Underwood W III, Fendrick AM, Bernstein SJ. Behavioral associations between prostate and colon cancer screening. J Am Coll Surg. 2005;200(2):216-223. doi:10.1016/j.jamcollsurg.2004.10.015

39. Fredman L, Sexton M, Cui Y, et al. Cigarette smoking, alcohol consumption, and screening mammography among women ages 50 and older. Prev Med. 1999;28(4):407-417. doi:10.1006/pmed.1998.0445

40. Gattellari M, Young JM, Ward JE. GP and patient predictors of PSA screening in Australian general practice. Fam Pract. 2003;20(3):294-303. doi:10.1093/fampra/cmg311

41. Rakowski W, Clark MA, Truchil R, Schneider K, Meersman S. Smoking status and mammography among women aged 50-75 in the 2002 behavioral risk factor surveillance system. Women Health. 2005;41(4):1-21. doi:10.1300/J013v41n04_01

42. Sutton S, Wardle J, Taylor T, et al. Predictors of attendance in the United Kingdom flexible sigmoidoscopy screening trial. J Med Screen. 2000;7(2):99-104. doi:10.1136/jms.7.2.99

43. Vander Weg MW, Howren MB, Cai X. Use of routine clinical preventive services among daily smokers, non-daily smokers, former smokers, and never-smokers. Nicotine Tob Res. 2012;14(2):123-130. doi:10.1093/ntr/ntr141

44. Bryant J, Bonevski B, Paul C, Lecathelinais C. Assessing smoking status in disadvantaged populations: is computer administered self report an accurate and acceptable measure? BMC Med Res Methodol. 2011;11:153. doi:10.1186/1471-2288-11-153

45. Patrick DL, Cheadle A, Thompson DC, Diehr P, Koepsell T, Kinne S. The validity of self-reported smoking: a review and meta-analysis. Am J Public Health. 1994;84(7):1086-1093. doi:10.2105/AJPH.84.7.1086

46. Baier M, Calonge N, Cutter G, et al. Validity of self-reported colorectal cancer screening behavior. Cancer Epidemiol Biomarkers Prev. 2000;9(2):229-232.

47. Rauscher GH, Johnson TP, Cho Yi, Walk JA. Accuracy of self-reported cancer-screening histories: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008;17(4):748-757. doi:10.1158/1055-9965.EPI-07-2629